Purpose We investigated the miRNA profile in peripheral nerve tumors and clarified the involvement of miRNA in the development and progression of MPNST in comparison with neurofibroma (NF). In addition, we attempted to seek associations between the miRNA and their potential targets in MPNST. Methods Global miRNA expression profiling was investigated for clinical samples of 6 MPNSTs and 6 NFs. As detected by profiling analysis, the expressions of miR-21 in clinical samples of 12 MPNSTs, 11 NFs, and 5 normal nerves, and 3 MPNST cell lines were compared using quantitative real-time reverse transcription PCR. MPNST cell line (YST-1) was transfected with miR-21 inhibitor to study its effects on cell proliferation, caspase activity, and the expression of miR-21 targets.
Introduction
Peripheral nerves are composed of various elements that arise from the neural crest and neural tube, such as Schwann cells, perineural cells, and fibroblasts. Peripheral nerve tumors can occur anywhere in the body; most are benign, such as schwannoma or neurofibroma (NF). However, malignant tumors can also arise from peripheral nerves, the most aggressive of which is malignant peripheral nerve sheath tumor (MPNST). MPNST constitutes 5-10 % of all soft tissue sarcomas. Approximately 80 % of MPNSTs are pathologically indicated as high-grade tumors, with a high incidence of local recurrence (40-65 %) and distant metastasis (40-68 %). The five-year survival rates of patients with MPNST at all sites are about 50 % (Enzinger and Weiss 2001) . MPNST can develop either spontaneously or in association with neurofibromatosis type 1 (NF1). NF1 is an autosomal dominant neurocutaneous disorder, which progresses to MPNST in about 10 % of patients (Ducatman et al. 1986 ). NF1 mutations (Wu et al. 1999) are one cause of tumorigenesis in MPNST, but recent reports have shown that germline and somatic NF1 alterations are not only found in MPNST, but are also found in NF (Bottillo et al. 2009; Upadhyaya et al. 2008) . Some papers have identified candidate genes in MPNST development, such as TP53 mutations (Lothe et al. 2001) and homozygous deletions of cyclin-dependent kinase inhibitor 2A (CDKN2A) (Berner et al. 1999; Nielsen et al. 1999) . However, the molecular events involved in MPNST tumorigenesis have not been fully investigated.
MicroRNAs (miRNAs) are endogenous 18-25 nucleotide, non-coding single-stranded RNAs that suppress protein expression by binding to complementary sequences of messenger RNA (mRNA). miRNA can bind to incomplete complementary sequences, meaning that each miRNA can regulate up to hundreds of target mRNAs. More than 1,000 miRNAs have been identified across the various species and found to regulate development, cell differentiation, cell proliferation, and apoptosis (Zhang 2008) . miRNA expression profiles are unique in tumors from different origins, and when overexpressed in malignant tumors, some miRNAs act similarly to oncogenes (Calin and Croce 2006) . Conversely, some miRNAs with tumor-repressor functions are downregulated in malignancies (Boominathan 2010) . Both normal and malignant tumor tissues may have specific miRNA expression patterns and show differential expression among tumor types. Although there have been many reports about the role of miRNAs in tumorigenesis, there are few reports about the role of miRNAs in soft tissue tumors.
In this study, we investigated the miRNA profile in peripheral nerve tumors and clarified the involvement of miRNA in the development and progression of MPNST in comparison with NF. In addition, we attempted to seek associations between the miRNAs and their potential targets in MPNSTs.
Materials and methods

Clinical samples
Tumor tissues were collected from patients who underwent surgical resection at the Okayama University Hospital. Normal nerves were obtained from tumor-free parts of amputated limbs. Written informed consent was obtained from each patient, and the use of specimens for analysis in this study was approved by an ethics committee at Okayama University. The tissues were immediately snap-frozen in liquid nitrogen and stored at -80°C until subsequent analysis.
Cell culture
The MPNST cell lines, HS-Sch-2, YST-1, and NMS-2, were provided by RIKEN BRC (Tsukuba, Japan) through the National Bio-Resource Project of MEXT, Japan. HS-Sch-2 was cultured in Dulbecco's modified Eagle medium (Wakochem, Osaka, Japan) containing 10 % fetal bovine serum, 100 lg/ml streptomycin, and 100 U/ml penicillin (Invitrogen, Carlsbad, CA, USA) (Sonobe et al. 2000) . YST-1 and NMS-2 were cultured in Roswell Park Memorial Institute-1640 medium (Wako-chem) with the same supplements (Nagashima et al. 1990; Imaizumi et al. 1998 ). Cells were maintained at 37°C in a 5 % CO 2 humidified incubator and subcultured using 0.25 % trypsin every 4-5 days before reaching confluence.
miRNA expression profiling
For global miRNA expression profiling, tissues comprised of six MPNSTs and six NFs were investigated. Total RNA was extracted from the cells and tissues using ISOGEN (NIPPON GENE, Tokyo, Japan). RNA concentrations were determined by NanoDrop ND-100 (NanoDrop Products, Wilmington, DE, USA). Quantitative real-time RT-PCR (qRT-PCR) analysis was performed using TaqMan Ò MicroRNA Assays Human PanelEarly Access Kit (Applied Biosystems, Foster city, CA, USA), which includes 157 mature human miRNAs. PCR was conducted at 95°C for 10 min followed by 40 cycles at 95°C for 15 s and 60°C for 60 s in the ABI 7500 Fast Real-time PCR system (Applied Biosystems). Total RNA samples (5 ng) were transcribed into cDNA with specific miRNA stem-loop primers, and PCR products were synthesized from cDNA samples using sequence-specific primers from the TaqMan Ò MicroRNA Assays Human Panel (Applied Biosystems). The assays were normalized to U6 RNA levels. miRNA expression in peripheral nerve tumors An additional experiment was carried out to confirm the data of the differentially expressed miRNAs, as detected by profiling analysis. Total RNA was isolated from another set of clinical samples (12 MPNSTs, 11 NFs, and 5 normal nerves) and three MPNST cell lines. qRT-PCR for mature miRNAs was performed using mirVana TM qRT-PCR miRNA Detection Kit and primers for miRNAs and U6 (Ambion, Austin, TX, USA). Real-time PCR analysis was performed with Power SYBR Ò Green PCR Master Mix and Mx300P TM (Agilent Technologies, Santa Clara, CA, USA).
PCR was conducted at 95°C for 3 min followed by 40 cycles of 95°C for 15 s and 58°C for 30 s. All PCRs were run in duplicate, and gene expression, relative to U6, was calculated using the comparative C T method (2 -DDCT ).
Knockdown of miR-21 in MPNST cells
The MPNST cell line, YST-1, was used to suppress miR-21 expression. Cells were transfected with an anti-miR TM miRNA inhibitor, miR-21 (Ambion), an miR inhibitor negative control #1 (scrambled-oligo-transfected controls), or FAM-labeled miR negative control inhibitor (mock), using siPORT TM NeoFX TM Transfection Agent (Ambion). YST-1 cells were transfected with 30 and 60 nM FAMlabeled miRNA inhibitor, and the ratio of FAM-labeled cells was calculated to assess transfection efficiencies. Twenty-four hours (h) after transfection, total RNA was extracted from the cells and miR-21 levels were assessed using qRT-PCR. For cell activity analysis and the caspase assay, cells were seeded into 96-well plates at 10,000 cells per well and treated with miRNA inhibitors, negative controls, and mock. The degree of apoptosis was assessed 48 h after transfection using the Caspase-Glo TM 3/7 Assay (Promega, Madison, WI, USA). Cell proliferation was measured 72 h after transfection using the CellTiter-Glo TM Luminescent Cell Viability Assay (Promega). The rate of absorbance was determined using a GloMax TM 20/20 Luminometer (Promega), and the results are presented as fold change compared to their respective untreated controls (mock).
Bioinformatics analysis
To understand the mechanism of action of miR-21 in MPNSTs, database research using TargetScan 5.1 (http:// www.targetscan.org), MicroCosm Targets V5 (http://www. ebi.ac.uk/enright-srv/microcosm/cgi-bin/targets/v5/search.pl), and PicTar (http://pictar.mdc-berlin.de/) was used to predict the targets of miR-21. These three programs each use a different algorithm to identify highly complementary sites and are widely used for miRNA target prediction. Therefore, genes predicted by all three algorithms were considered to be targets.
Western blot analysis
Cell lysates for Western blot analyses were prepared from cells 72 h after transfection and from clinical samples of MPNSTs, NFs, and normal nerves. Total protein from cell lysates (15 lg/lane) were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a 10 % gel and then transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories, Hercules, CA, USA). Membranes were blocked with Blocking Reagent (TOYOBO, Osaka, Japan) and incubated with anti-PDCD4 (ROCKLAND, Gilbertsville, PA, USA) and anti-beta actin (Sigma, St. Louis, MO, USA) at a dilution of 1:1,000 in CanGet Signal Immunoreaction Enhancer Solution (TOYOBO) for 1 h at room temperature. The membranes were washed with washing buffer and incubated with horseradish peroxidase-conjugated antimouse (diluted 1:10,000, R&D Systems) or anti-rabbit (diluted 1:50,000, Bethyl Laboratories, Montgomery, TX, USA) secondary antibodies for 1 h at room temperature. Immunoreactive proteins were detected using the ECL Detection System (GE Healthcare, Buckinghamshire, UK). Densitometry was carried out using Image J software (NIH, Bethesda, MD, USA), and protein content was normalized according to b-actin content.
Statistical methods
The expression levels were analyzed by Student's t-test. P values \0.01 were considered statistically significant in miRNA expression profiling and P values \0.05 in other analyses. Statistical analysis was performed using StatView software, version 5.0 (SAS Institute Inc., Cary, NC, USA). For miRNA expression profiling, a cluster analysis was performed using TM4 MeV 4.4 software via the open-source MeV software tool available from http://www.tm4.org/ mev.html (Saeed et al. 2003) .
Results
miRNA expression profiling
We compared the miRNA expression profiles of six MPNSTs with those of six NFs and identified nine miRNAs that showed significantly different expression levels between the tumors (Table 1) ; the expression levels of miR-21, miR-135b, miR-152, miR-130b, miR-92, and miR-15b were increased in MPNST, whereas the expression levels of miR-125b, miR-127, and miR-302d were increased in NFs. Unsupervised hierarchical clustering, based on the expression levels of these nine miRNAs, almost segregated MPNSTs from NFs and was not dissociable between patients with NF1 and non-NF1 (Fig. 1) .
Validation of miRNA expression profiling
As a confirmation of profiling analysis, we quantified expressions of miR-21, miR-135b, miR-125b, miR-127, and miR-302d in clinical samples from NFs, MPNSTs, and normal peripheral nerves, and three MPNST cell lines, since there were statistical differences with more than twofold change between these miRNAs expression in MPNSTs and in NFs (Table 1) . Among 5 miRNAs, the expression level of miR-21 in clinical samples of MPNSTs was significantly higher than that in NFs and normal nerves (Fig. 2a) . In contrast, miR-21 expression in NFs was similar to that in normal nerves. The expression of miR-21 in MPNST cell lines was also significantly higher than that in normal nerves (Fig. 2f) . Based on these results, we proceeded with further analysis on miR-21 function in MPNSTs and NFs.
miR-21 inhibitor in MPNST cells
We characterized the function of miR-21 in MPNST cells. YST-1 cells were transfected with a specific miR-21 inhibitor to silence miR-21 expression. Transfection efficiency, as a ratio of FAM-labeled miRNA-positive cells, was 31 and 22 %, respectively, at concentrations of 30 nM and 60 nM (Fig. 3) . We conducted further analysis using miR-21 inhibitor at concentration of 30nM, which resulted in better transfection efficiency. The expression level of miR-21 in YST-1 cells transfected with miR-21 inhibitor was significantly reduced to 66 % of that in the mock-transfected cells (P \ 0.05, Fig. 4a) . A caspase assay showed that transfection with miR-21 inhibitor significantly increased apoptosis in YST-1 cells by 150 % when compared to mock-transfected cells (P \ 0.01, Fig. 4b ). Cells transfected with miR-21 inhibitor showed significantly lower cell proliferation (80 %) than mock-transfected cells (P \ 0.05, Fig. 4c ).
Functional analysis of miR-21 in MPNST cells
In order to further investigate the action of miR-21 in MPNST, we next sought to determine the miR-21-target RNA. The potential miR-21-targets were predicted using three different algorithms. Overall, 1,000 hits were found in microcosm, 210 in TargetScan, and 175 in PicTar, with 22 overlapping targets ( Table 2) . Among these mRNAs, we noticed PDCD4, a previously reported target of miR-21 that is thought to act as a tumor suppressor gene (Young et al. 2010 ; Lankat-Buttgereit and Göke 2009). We examined whether miR-21 inhibits the protein synthesis of PDCD4. Western blot analyses demonstrated that an miR-21 inhibitor increased PDCD4 protein synthesis by approximately 40 % in transfected cells (Fig. 5) , although PDCD4 mRNA levels were unchanged (data not shown). Next, we examined the expression of PDCD4 protein in clinical samples of MPNSTs, NFs, and normal nerves. Protein expression levels of PDCD4 were twofold higher in NFs than in MPNSTs (P \ 0.05, Fig. 6 ) and threefold higher in normal nerves than in MPNSTs (P \ 0.01); however, once again, there were no significant differences in PDCD4 mRNA levels among them (data not shown). 
Discussion
In the present study, miRNA expression profiling demonstrated that nine miRNAs were differentially expressed between NFs and MPNSTs. These nine miRNAs were considered candidate genes that could influence the tumorigenesis of MPNST or malignant conversion in NF. Previous papers have shown that these miRNAs are associated with tumor progression in other malignant tumors:
miR-125b in breast cancer Saetrom et al. 2009 ), bladder cancer , and liver cancer (Alpini et al. 2011 ); miR-152 in gastrointestinal cancer (Chen et al. 2010 ); miR-130 in chronic myelogenous lymphoma (Suresh et al. 2011 ); miR-127 in diffuse large B-cell lymphoma (Robertus et al. 2009 ); miR-92 in neuroblastoma, breast cancer, and acute leukemia (Haug et al. 2011; Al-Nakhle et al. 2010; Tanaka et al. 2009 ); and miR-15b in malignant melanoma (Satzger et al.2010) . Recent studies have also focused on the potential roles of miRNA in cancer prognosis, chemosensitivity, and multidrug resistance in bone and soft tissue sarcomas as well as other forms of malignancy (Greither et al. 2011; Song et al. 2010; Missiaglia et al. 2010) . MPNST is a rare malignant tumor, and an optimal treatment strategy, including chemotherapy, has not yet been confirmed. Our small set of MPNST patients underwent various treatments, but we could make no correlations between clinical outcome of our patients and miRNA expression. Two studies have examined miRNA in MPNSTs. Subramanian et al. (2010) assessed miRNA expression profile in 23 peripheral nerve sheath tumors (including six MPNSTs) and identified 10 miRNAs that were up or downregulated in comparison with NF and schwannoma.
In particular, the authors demonstrated that miR-34a transcript levels may depend on p53 activation, and they showed that apoptosis could be induced in MPNST cells transfected with miR-34a. Since we only compared miR-NA expression profiles in MPNSTs with those of NFs, the current study could not identify differences in miR-34a expression between the tumors. In the second study, Chai et al. (2010) reported that the expression level of miR-10b was higher in NF1-associated MPNST than in non-NF1-associated MPNSTs and concluded that miR-10b may play an important role in NF1 tumorigenesis through targeting neurofibromin and RAS signaling. Our MPNST samples MPNST cell lines. The expression level of miR-21 in clinical samples from MPNSTs was significantly higher that than in NFs. miR-21 expression in MPNST cell lines was also significantly higher than that in normal nerves (f). *P \ 0.05, **P \ 0.01 included non-NF1-associated samples, and we analyzed both NF1 and non-NF1. This may explain why our miRNA profiling did not suggest the importance of miR-10b in MPNST tumorigenesis. Higher expression of miR-21 was detected in several types of cancers as well as soft tissue tumors (Folini et al. 2010; Zhang et al. 2008) , and miR-21 could be a key regulator of oncogenic processes (Si et al. 2007; Selcuklu and Donoghue 2009). Cioffi et al. (2010) revealed that miR-21 overexpression contributes to vestibular schwannoma cell proliferation and prognosis. In leiomyoma, miR-21 was overexpressed and regulated TGF-b-RII, E2F1, PTEN, and PDCD4 (Pan et al. 2010 ). In our study, the The membranes were blotted with PDCD4 and GAPDH antibody. Intensities of each protein band were detected using ECL Detection System and analyzed using Image J software (NIH). The results are presented as fold change compared to their respective untreated controls (mock). Inhibitor miR-21 inhibitor, NC negative control expression of miR-21 was significantly higher in MPNSTs than in NFs and normal nerves, suggesting that the miR-21 might be an important progression factor in the malignant development of peripheral nerve tumors.
From the database search, we focused on PDCD4 as the target of miR-21, since PDCD4 expression has been reported in several malignant tumors (Wei et al. 2009; Chen et al. 2003; Afonja et al. 2004 ) and is also targeted by miR-21 (Qi et al. 2009; Frankel et al. 2008; Asangani et al. 2008 ). In the current study, miR-21 inhibitor induced caspase 3/7 activity in the MPNST cell line and decreased cell proliferation, despite moderate transfection efficiency. Furthermore, PDCD4 was upregulated by the miR-21 inhibitor in MPNST cells. PDCD4 was upregulated by the miR-21 inhibitor in many malignant tumors (Gaur et al. 2011; Si et al. 2007; Chan et al. 2005) . The expression of PDCD4 is increased during apoptosis (Lankat-Buttgereit and Göke 2009; Allgayer 2010). The overexpression of PDCD4 might induce apoptosis via caspase cascade (Lankat-Buttgereit and Göke 2009; Zhang et al. 2006 ). These results suggested that inhibition of miR-21 could increase PDCD4 expression and lead to apoptosis of tumor cells through caspase activation in MPNSTs. PDCD4 has been also known as the tumor suppressor that inhibits neoplastic transformation, tumor progression, and translation and is decreased in human carcinogenesis (Young et al. 2010; Lankat-Buttgereit and Göke 2009; Wei et al. 2009; Frankel et al. 2008 ). The present study demonstrated that PDCD4 expression was suppressed in clinical samples from MPNST patients when compared to samples from NF patients. The overexpression of miR-21 could suppress PDCD4 function in MPNST and result in decreasing apoptosis and increasing cell proliferation as an oncogene.
The expression of PDCD4 mRNA did not differ in the MPNST cell line or in clinical samples, as the expression of PDCD4 protein was decreased. Asangani et al. (2008) also reported that PDCD4 mRNA was unaltered by inhibition of miR-21 as opposed to a significant change in PDCD4 protein in colorectal cancer. miRNAs can bind to complementary sites in the mRNA target to negatively regulate target gene expression at the post-transcriptional level (Zhang 2008; Bartel et al. 2004) . We proposed that the main mechanism of miR-21-induced PDCD4 suppression might be post-transcriptional, as suggested previously (Asangani et al. 2008 ).
In conclusion, our miRNA expression profiling and validation analyses suggest that miR-21 plays an important role in MPNST tumorigenesis and progression through its target, PDCD4. Together, these results indicate that miR-21 and PDCD4 may be candidate novel therapeutic targets against the development or progression of MPNSTs. 
